St. Jude Children's Research Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, St. Jude Children's Research Hospital sits in the top decile of US sponsors by registered trial count (#87 of 15,742 sponsors by registered trial count).
St. Jude Children's Research Hospital: 410 sponsored US clinical trials, 90 recruiting.
St. Jude Children's Research Hospital sponsors 410 registered US clinical trials on ClinicalTrials.gov, 90 of them currently recruiting, and 227 completed. 19 of these trials are in Phase 3-4 (later-stage) and 173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sickle Cell Disease, with 17 trials.
Top-decile sponsor footprint
St. Jude Children's Research Hospital ranks in the top decile of sponsors by registered trial count (#87 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
227 of 259 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
410 total, page 8 of 9
Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound
NCT00152113
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
NCT00186940
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
NCT00124657
Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults
NCT00187148
Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies
NCT00718757
Study of Stored Tumor Samples in Young Patients With Brain Tumors
NCT00897286
Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease
NCT00143572
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
NCT00187174
Stem Cell Transplantation for Children Affected With Osteopetrosis
NCT00145587
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
NCT00145626
Trial of Oral Glutamine in Patients With Sickle Cell Anemia
NCT00131508
Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study
NCT00187018
Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome
NCT00152100
Family-Staff Communication Intervention at the Time of Difficult Treatment Decision Making
NCT00827437
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00186875
Pilot Test for a Newly Developed Nutrition Screening Method: Pediatric Subjective Global Assessment
NCT00665691
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
NCT00143533
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
NCT00085202
Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas
NCT00152126
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
NCT00145613
Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors
NCT00186979
Testing the Effectiveness of Child and Parent-Targeted Health Promotion Interventions in Pediatric Stem Cell Transplantation
NCT00760227
Radiofrequency Ablation of Tumors
NCT00705497
Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia
NCT00186797
A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor
NCT00187031
Reduction of Environmental Tobacco Smoke (ETS) Exposure In Pediatric Cancer Patients
NCT00766766
Study for Treatment of Cancer in Children With Ataxia-telangiectasia
NCT00187057
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
NCT00136084
Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors
NCT00186953
Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00152139
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00186823
Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration
NCT00187135
AVN of Weight-Bearing Joints In Patients With Hematologic Malignancies Treated With Dexamethasone Or Prednisone
NCT00719147
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
NCT00137111
A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors
NCT00186901
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
NCT00187109
Oxaliplatin in Treating Children With Advanced Solid Tumors
NCT00005844
Therapy for Pediatric Hodgkin Lymphoma
NCT00145600
Learning Impairments Among Survivors of Childhood Cancer
NCT00576472
Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation
NCT00186914
Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma
NCT00145639
Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor
NCT00004068
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
NCT00004005
Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma
NCT00186862
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
NCT00187005
Large Cell Lymphoma Pilot Study III
NCT00187070
Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma
NCT00004006
Evaluation of the Safety of a Polyvalent Virus in Healthy Adults
NCT00187044
Therapy for Children With Advanced Stage High Risk Neuroblastoma
NCT00186849
A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects
NCT00187226
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 86 |
| Phase 3 | 17 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the St. Jude Children's Research Hospital pipeline
90 recruiting of 410 indexed (22% open); 227 completed (55%).
Phase mix: 19 late (III/IV) vs 173 early (I/II) (early-phase heavy).
Top condition: Sickle Cell Disease (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
St. Jude Children's Research Hospital: open-pipeline peers nationwide
Peers matched on 410 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
St. Jude Children's Research Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 410 trials (± recruiting share)
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- Rutgers, The State University of New Jersey · 413 trials · 26% recruiting
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Northwell Health · 22% recruiting · 370 trials
- Vanda Pharmaceuticals · 22% recruiting · 68 trials
- Boston University Charles River Campus · 22% recruiting · 104 trials
- Regeneron Pharmaceuticals · 22% recruiting · 280 trials
Related
What to do with this St. Jude Children's Research Hospital page
410 registered trials is a research-attention snapshot, not an endorsement of St. Jude Children's Research Hospital or any single study.
- 90 of St. Jude Children's Research Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sickle Cell Disease is the condition St. Jude Children's Research Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sickle Cell Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. St. Jude Children's Research Hospital pipeline card: 410 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.